Implante de stent eluído com batimastat para o tratamento da doença arterial coronariana: resultados do estudo piloto brasileiro

Araújo, Cristiana Marques de; Rando, Gustavo Adolfo B; Mauro, Maria Fernanda Zuliani; Cristóvão, Salvador André Bavaresco; Sánchez, I. Sanz; Salman, Adnan Ali; Neto, João Batista; Mangione, José Armando

doi:10.1590/s0066-782x2005000300012

Cited by 4 publications

(2 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The results of these human studies showed neither angiographic improvement nor a decreased requirement for endoluminal reintervention as a result of MMP inhibition. 85,86 It is unclear if these disappointing findings are the result of limitations in drug delivery, incomplete MMP inhibitory activity of the drugs, or if these studies simply demonstrate the ineffectiveness of MMP inhibition in reducing restenosis. Because the results of these primate and human studies contradict the data obtained from lower animal studies, further investigations are clearly necessary to determine if MMP inhibition has a role in the treatment of arterial restenosis by intimal hyperplasia and constrictive remodeling.…”

Section: Restenosis After Vascular Interventionmentioning

confidence: 99%

Matrix metalloproteinases in peripheral vascular disease

Hobeika

Thompson

Muhs

et al. 2007

Journal of Vascular Surgery

View full text Add to dashboard Cite

Matrix metalloproteinases (MMPs) are extracellular matrix-modifying enzymes that are important in many physiologic and pathologic vascular processes. Dysregulation of MMP activity has been associated with common vascular diseases such as atherosclerotic plaque formation, abdominal aortic aneurysms, and critical limb ischemia. For this reason, MMPs have become an important focus for basic science studies and clinical investigations by vascular biology researchers. This article reviews the recent literature, summarizing our current understanding of the role of MMPs in the pathogenesis of various peripheral vascular disease states. In addition, the importance of MMPs in the future diagnosis and treatment of peripheral vascular disease is discussed.

show abstract

Section: Restenosis After Vascular Interventionmentioning

confidence: 99%

Matrix metalloproteinases in peripheral vascular disease

Hobeika

Thompson

Muhs

et al. 2007

Journal of Vascular Surgery

View full text Add to dashboard Cite

show abstract

“…Basic inhibition involves chelation of the active site zinc ion with the addition of alternative affinity sites to provide specificity and attempt to minimize side effects, most notably the musculoskeletal syndrome [148,149]. Several synthetic nonselective MMP inhibitors have been constructed but studies of systemic as well as local administration have failed to demonstrate a meaningful impact on vascular remodeling, though it ought to be noted that very few of these investigations focused on peripheral arteries [150,151,152,153]. Doxycycline, a downregulator of general MMP activity, is currently approved in a low-dose form to treat periodontal disease, but its efficacy in attenuating atherosclerotic disease has been questionable [154].…”

Section: Targets To Promote Plaque Stabilizationmentioning

confidence: 99%

Multidimensional Contribution of Matrix Metalloproteinases to Atherosclerotic Plaque Vulnerability: Multiple Mechanisms of Inhibition to Promote Stability

Ruddy¹,

Ikonomidis²,

Jones³

2016

J Vasc Res

View full text Add to dashboard Cite

The prevalence of atherosclerotic disease continues to increase, and despite significant reductions in major cardiovascular events with current medical interventions, an additional therapeutic window exists. Atherosclerotic plaque growth is a complex integration of cholesterol penetration, inflammatory cell infiltration, vascular smooth muscle cell (VSMC) migration, and neovascular invasion. A family of matrix-degrading proteases, the matrix metalloproteinases (MMPs), contributes to all phases of vascular remodeling. The contribution of specific MMPs to endothelial cell integrity and VSMC migration in atherosclerotic lesion initiation and progression has been confirmed by the increased expression of these proteases in plasma and plaque specimens. Endogenous blockade of MMPs by the tissue inhibitors of metalloproteinases (TIMPs) may attenuate proteolysis in some regions, but the progression of matrix degeneration suggests that MMPs predominate in atherosclerotic plaque, precipitating vulnerability. Plaque neovascularization also contributes to instability and, coupling the known role of MMPs in angiogenesis to that of atherosclerotic plaque growth, interest in targeting MMPs to facilitate plaque stabilization continues to accumulate. This article aims to review the contributions of MMPs and TIMPs to atherosclerotic plaque expansion, neovascularization, and rupture vulnerability with an interest in promoting targeted therapies to improve plaque stabilization and decrease the risk of major cardiovascular events.

show abstract

Batimastat

Townsend¹

2007

xPharm: The Comprehensive Pharmacology Reference

View full text Add to dashboard Cite

Implante de stent eluído com batimastat para o tratamento da doença arterial coronariana: resultados do estudo piloto brasileiro

Abstract: Batimastat-eluting stents had a good safety profile; however, they were not effective in controlling coronary restenosis.

Cited by 4 publications

References 37 publications

Matrix metalloproteinases in peripheral vascular disease

Matrix metalloproteinases in peripheral vascular disease

Multidimensional Contribution of Matrix Metalloproteinases to Atherosclerotic Plaque Vulnerability: Multiple Mechanisms of Inhibition to Promote Stability

Batimastat

Contact Info

Product

Resources

About